Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
March 3, 2026
ROS-responsive Prussian blue nanoplatform for synergistic myocardial ischemia/reperfusion injury therapy via EGCG delivery and DJ-1 pathway regulation
JZ
Jianan Zhang
YH
Yangli He
YW
Yundi Wu
Hainan University
See all
Key Points
Improved myocardial ischemia/reperfusion injury outcomes highlight the efficacy of the novel nanoplatform.
The study demonstrated a significant reduction in injury markers through DJ-1 pathway regulation by the nanoplatform.
Assessment using a ROS-responsive Prussian Blue nanoplatform facilitated effective EGCG delivery for cardiac protection.
These findings may enable new therapeutic approaches for cardiac injury, but further clinical validation is needed.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Zhang et al. (Wed,) studied this question.
synapsesocial.com/papers/69a75d02c6e9836116a26643
https://doi.org/https://doi.org/10.1016/j.ijpharm.2026.126620
ROS-responsive Prussian blue nanoplatform for synergistic myocardial ischemia/reperfusion injury therapy via EGCG delivery and DJ-1 pathway regulation | Synapse